切换导航
About Us
Our Story
Our Mission
History
Global Footprint
Leadership
Board of Directors
Science & Technology
Pipeline
Collaborations
CDMO Services
About CDMO
Strength
Services Offered
Learn More
Investors & Media
Join Us
EN
中文
Home
>
Investors & Media
Investors & Media
Immorna has successfully closed 3 rounds of financing with a total of 8 investors, including leading venture capitals and industry investors.
We welcome new investors. For investment
opportunities, please contact
ir@immornabio.com
News Flow
News Update
Immorna Biotherapeutics Announces First Clinical Administration of JCXH-213, a Breakthrough mRNA-based In Vivo CAR Therapy
ImmornaBiotherapeutics today announced the successful dosing of the first patient in itsclinical stu...
View More
2025.03
News Update
Immorna Receives Grant from Bill & Melinda Gates Foundation to Support Its mRNA RSV Vaccine Clinical Development
Research Triangle Park, NC Aug 14, 2024 – Immorna Biotherapeutics Inc. (Immorna) today announces tha...
View More
2024.08
News Update
Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors
MORRISVILLE, N.C., July 8, 2024 /PRNewswire/ -- ImmornaBiotherapeutics, Inc. (Immorna), a clinical s...
View More
2024.07
News Update
Immorna Biotherapeutics Presents Clinical Data for JCXH-211, a Self-Replicating RNA Encoding the Human IL-12, at ASCO 2024
Immorna Biotherapeutics PresentsClinical Data for JCXH-211, a Self-Replicating RNA Encoding the Huma...
View More
2024.06
News Update
Immorna Announces First Subject Dosed in a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Vaccine Developed for the Prevention of Shingles
MORRISVILLE, N.C., May 30, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company f...
View More
2023.05
News Update
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
MORRISVILLE, N.C., January 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology compan...
View More
2023.01
News Update
Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine
MORRISVILLE, N.C., November 21st, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology co...
View More
2022.11
News Update
First Patient Dosed in Phase 1 FIH Study of JCXH-211, the First-in-Class Self-Replicating RNA encoding human IL-12, in Patients with Malignant Solid Tumors
Immorna Announces First Patient Dosed in Phase 1 FIH Study of JCXH-211, the First-in-Class Self-Repl...
View More
2022.11
News Update
Immorna’s mRNA Quadrivalent Seasonal Influenza Vaccine Obtains US. FDA IND Clearance
US. Eastern Time, July 27 2023, Immorna Biotherapeutics, Inc ("Immorna") announces that i...
View More
2023.07
Immorna Receives IND Clearance to Conduct FIH Study of JCXH-211, the First-in-Class Self-replicating mRNA
Encoding Human IL-12 Protein, in Cancer PatientsRALEIGH, N.C., March 28, 2022 /PRNewswire/ -- Immor...
View More
2022.03
Immorna Expands Its R&D Footprint in RTP, NC and Appoints Key Senior Scientific Leaders
RALEIGH, N.C., Jan. 31, 2022 /PRNewswire/ -- Immorna Biotherapeutics, Inc, an immune-oncology drug a...
View More
2022.01
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a l...
View More
2021.07
China’s Kangtai Biological Partners With Startup to Develop mRNA Vaccines
(Yicai Global) July 19 -- Leading Chinese vaccine developer Kangtai Biological Products said it plan...
View More
2021.07
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms
SHANGHAI and GAITHERSBURG, Md., July 9, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...
View More
2021.07